BACKGROUND: Evidence for basal hypothalamic-pituitary-adrenal (HPA) axis dysfunction in schizophrenia is less consistent than that seen in major depression. Potential reasons include sampling procedures and the use of patients on antipsychotic medications which may suppress the HPA axis. Therefore, the objective of this study was to determine whether first episode, drug naïve patients with schizophrenia have evidence of basal HPA axis dysfunction by measuring plasma levels of AVP, ACTH and cortisol from 13:00 to 16:00 h, a time frame which is believed to reflect 24 h concentrations of HPA axis activity. METHOD: In this cross-sectional study, plasma levels of AVP, ACTH and cortisol were measured in 12 (7 males and 5 females) (mean age +/-SD=33.6+/-12.6 years) patients with DSM-IV schizophrenia and compared with those found in age- and sex-matched healthy controls. RESULTS: Patients and controls did not differ in terms of their 13:00 h cortisol and AVP. However, patients with schizophrenia had higher levels of ACTH as compared to control subjects at 13:00 h (41.3+/-14.6 vs. 12.4+/-1.1 pg/ml respectively; t=1.99, df=11, p <0.05). In comparison to controls subjects, patients with schizophrenia, had higher mean (+/-SE) AUC of ACTH (26.3+/-6.2 vs. 13.9 nmol/l, respectively; t=2.86, df=11, p <0.02) and cortisol (279.4+/-26.0 vs. 213.1+/-18.4 nmol/l, respectively; t=3.72, df=11, p <0.01). Though, patients with schizophrenia, in comparison to control subjects, had lower mean (+/-SE) AUC of AVP (0.87+/-0.24 vs. 1.42+/-0.34 pmol/l, respectively; t=2.29, df=11, p <0.02). CONCLUSIONS: First episode, drug naïve patients with schizophrenia show evidence of basal overactivity of the pituitary-adrenal axis.
BACKGROUND: Evidence for basal hypothalamic-pituitary-adrenal (HPA) axis dysfunction in schizophrenia is less consistent than that seen in major depression. Potential reasons include sampling procedures and the use of patients on antipsychotic medications which may suppress the HPA axis. Therefore, the objective of this study was to determine whether first episode, drug naïve patients with schizophrenia have evidence of basal HPA axis dysfunction by measuring plasma levels of AVP, ACTH and cortisol from 13:00 to 16:00 h, a time frame which is believed to reflect 24 h concentrations of HPA axis activity. METHOD: In this cross-sectional study, plasma levels of AVP, ACTH and cortisol were measured in 12 (7 males and 5 females) (mean age +/-SD=33.6+/-12.6 years) patients with DSM-IV schizophrenia and compared with those found in age- and sex-matched healthy controls. RESULTS:Patients and controls did not differ in terms of their 13:00 h cortisol and AVP. However, patients with schizophrenia had higher levels of ACTH as compared to control subjects at 13:00 h (41.3+/-14.6 vs. 12.4+/-1.1 pg/ml respectively; t=1.99, df=11, p <0.05). In comparison to controls subjects, patients with schizophrenia, had higher mean (+/-SE) AUC of ACTH (26.3+/-6.2 vs. 13.9 nmol/l, respectively; t=2.86, df=11, p <0.02) and cortisol (279.4+/-26.0 vs. 213.1+/-18.4 nmol/l, respectively; t=3.72, df=11, p <0.01). Though, patients with schizophrenia, in comparison to control subjects, had lower mean (+/-SE) AUC of AVP (0.87+/-0.24 vs. 1.42+/-0.34 pmol/l, respectively; t=2.29, df=11, p <0.02). CONCLUSIONS: First episode, drug naïve patients with schizophrenia show evidence of basal overactivity of the pituitary-adrenal axis.
Authors: Stefan Busse; Hans-Gert Bernstein; Mandy Busse; Hendrik Bielau; Ralf Brisch; Christian Mawrin; Susan Müller; Zoltán Sarnyai; Tomasz Gos; Bernhard Bogerts; Johann Steiner Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-12-14 Impact factor: 5.270
Authors: M Aas; P Dazzan; V Mondelli; T Toulopoulou; A Reichenberg; M Di Forti; H L Fisher; R Handley; N Hepgul; T Marques; A Miorelli; H Taylor; M Russo; B Wiffen; A Papadopoulos; K J Aitchison; C Morgan; R M Murray; C M Pariante Journal: Psychol Med Date: 2010-06-09 Impact factor: 7.723
Authors: Johannes Lieslehto; Vesa Kiviniemi; Pirjo Mäki; Jenni Koivukangas; Tanja Nordström; Jouko Miettunen; Jennifer H Barnett; Peter B Jones; Graham K Murray; Irma Moilanen; Tomáš Paus; Juha Veijola Journal: Hum Brain Mapp Date: 2017-06-14 Impact factor: 5.038
Authors: Tammy M K Cheng; Yu-En Lu; Paul C Guest; Hassan Rahmoune; Laura W Harris; Lan Wang; Dan Ma; Victoria Stelzhammer; Yagnesh Umrania; Matt T Wayland; Pietro Lió; Sabine Bahn Journal: Mol Cell Proteomics Date: 2009-12-10 Impact factor: 5.911
Authors: H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153
Authors: Valeria Mondelli; Carmine M Pariante; Serena Navari; Monica Aas; Alessandro D'Albenzio; Marta Di Forti; Rowena Handley; Nilay Hepgul; Tiago Reis Marques; Heather Taylor; Andrew S Papadopoulos; Katherine J Aitchison; Robin M Murray; Paola Dazzan Journal: Schizophr Res Date: 2010-01-13 Impact factor: 4.939